**Reviewer’s Comments**

#

*PORPHYROMONAS GINGIVALIS*: BIOFILM FORMATION, ANTIMICROBIAL SUSCEPTIBILITY OF ISOLATES FROM CASES OF LOCALIZED AGGRESSIVE PERIODONTITIS (LAP)

**ABSTRACT**

**Background**:No information is available on the antimicrobial sensitivity pattern and guidelines for oral antibiotic therapy for Yemeni patients for those with localized aggressive periodontitis (LAP) due to *Porphyromonas gingivalis*, a condition that often requires complementary antibiotic treatment.**Aim:**The primary objective of this study was to examine the antibiotic patterns and the potential relationship between *P.gingivalis* biofilm formation and the incidence of antibiotic resistance of clinical isolates on a group of antibiotics commonly used in oral/systemic therapy. **Materials and Methods**:The study included 30 strains of *P.gingivalis* isolated from LAP patients. Microbial sampling, isolation, and identification of bacteria were performed using culture methods appropriate to anaerobic species.Biofilm production was evaluated by the phenotypic method, that is, tissue culture methods (TCPM). Also; each isolate was tested against 12 antibiotics using the disc diffusion method according to theClinical and Laboratory Standards Institute (CLSI).**Results:**After isolated *P.gingivalis*were subjected to biofilm detection by TCP method, 7 (23.3%) showed high, 6 (20%) moderate, while 17 (56.7%) showed non/weak biofilm-forming ability. *P.gingivalis*biofilms showed a higher resistance rate than forming non/weak biofilms e.g amoxicillin (92.3% vs 64.7%, *p* = 0.08), azithromycin (58.8% vs 11.7, *p*=0.003), metronidazole (76.9% vs 29.4%, *p* = 0.08), 0.01) and clindamycin (84.6% vs 47.1, *p* = 0.03).Regarding all antibiotic sensitivity findings: cefotaxime, ceftriaxone and moxifloxacin showed excellent activity at 100% sensitivity, followed by amoxiclav (90%), tetracycline (83.3%), cefuroxime (80%), cefazolin (73.3%) and azithromycin (63.3%).In addition, ~~Bacterial~~ strains showed poor sensitivity to clindamycin, doxycycline, metronidazole and amoxicillin.**Conclusion**:It was found that the drug-resistant factor in *P.gingivalis* isolates is associated with the formation of *P.gingivalis* biofilm. Even though the present results show a high sensitivity pattern for P. gingivalis strains, some resistance has been observed. Antibiotic resistance patterns can change over the years, making susceptibility testing essential and to promote careful selection of initial antibiotic therapy, as an adjuvant to endodontic therapy.

**KEYWORDS:** antibiotic resistance, biofilm formation, *Porphyromonas gingivalis*, disc diffusion method.

**INTRODUCTION**

Amongst the major periodontal pathogens, *P. gingivalis* shows to be one of the major etiological factors in the pathogenesis and development of inflammatory proceedings of periodontal disease 1. These bacteria were obtained in 85.75% of subgingival plaque samples from chronic periodontitis patients. This Gram-negative, non-motile, non-saccharolytic bacterium is an compulsory anaerobic rod that forms black-coloured colonies on blood agar plates and has an obvious prerequisite for iron in its growth2.The main habitat of *P. gingivalis* is the subgingival sulcus in the oral cavity of human. It depends on the fermentation of amino acids to produce energy, a property that is required for its survival in the deep pocket of the teeth, where the availability of sugar is low3. Being a binding anaerobic, *P. gingivalis* acts as a secondary colonizer for dental plaques, often observing primary colonizers such as *Streptococcus gordonii* and *P. intermedia*3. The maintenance and growth of *P.gingivalis* on various surfaces is assisted by a group of adhesives including fimbriae, hemagglutinins and enzyme proteins; and this makes it capable of biofilm formation4. A biofilm consists of any synthetic association of microorganisms (including yeast and bacteria) in which cells adhere to each other and often also to the surface5,6. These adherent cells become embedded in a sticky extracellular matrix composed of extracellular polymeric substances (EPSs). Cells within biofilms produce components of EPS, which are usually a polymeric conglomerate of sugars, proteins, lipids, and extracellular DNA5. Porphyromonas acquires a large number of recognized virulence determinants, suggesting that it may be one of the most pathogenic species established in the oral cavity. These include haemagglutinin, fimbriae, outer membrane vesicles, capsule, lipopolysaccharide (LPS), and have strong hydrolytic activities that can disturb host defense mechanisms plus initiate tissue impairment2,3.

Even though *P. gingivalis* clinical isolates tend to be sensitive to nearly all antimicrobial agents and usually do not create *β-lactamase*, comparatively insignificant information is obtainable on antibiotic susceptibility in vitro. Moreover, antibiotic resistance between anaerobes is constantly increasing which may be connected to the selective pressure exerted by antibiotic use. Determination of susceptibility to antimicrobials in vitro can be vital in specific circumstances, for example, to monitor patterns of sensitivity and resistance in a population and to assist in the assortment of an suitable antibiotic whilst implied in endodontic therapy7. The disc diffusion method was assessed to determine the sensitivity pattern of different antimicrobial agents against oral anaerobic bacteria and it was found to be appropriate8-10.

Though there are some studies of oral and dental problems in Yemen9-17, the antimicrobial susceptibility pattern of *P. gingivalis* isolated from localized aggressive periodontitis (LAP), no study discusses the antimicrobial susceptibility pattern of *P. gingivalis* . The current study was planned in an adult population in Sana'a city, in Yemen (1) to determine the levels of *P. gingivalis* biofilm formation (2) also to detect antibacterial sensitivity of *P. gingivalis* isolate (3) and study the relationship between biofilm formation and antibiotic resistance.

**MATERIALS AND METHODS**

**Patients:**This study included 30 patients clinically and radiologically confirmed with LAP, who were admitted to the dental clinic at the Republican University Hospital and private dental clinics (Al-Mortadda dental clinics, Al-Abany dental clinics and Al-Kahara dental clinics) in Sana'a, during a period of more than one year, which started in December 2019 and ended in February 2021.

Microbiological examination

The culturing and antibiotic sensitivity were conducted in the Microbiology Department of the National Center of Public Health Laboratories (NCPHL) Sana'a, Yemen. Cultures were obtained from the collected pocket by probes in order to isolate the various bacterial causative agents. First, the supragingival plaque was removed (without disturbing the subgingival plaque) and a bacterial sample was collected from the deepest periodontal pockets with a sterile probe. The samples were then placed in a vial containing 2 ml of liquid thioglycolate enriched medium, sealed immediately and transported to the laboratory within 30 minutes. Bacteriological procedures were performed within one hour of sample collection. For germ cultures, the following media and conditions were used: Tryptic Soy Agar (TSA) with blood (5%) and MacConkey agar plates - incubated at 35°C under 5% CO2 and examined at 24 and 48 hours; Brucella agar enriched with Vitamin K1 and CDC + amikacin blood agar - incubated at 35°C anaerobically in a Gaspak jar (Oxoid Ltd). Cultures were examined for the presence of bacteria at 48 and 96 h. Plates showing bacterial growth were retained until final processing and organism identification by classical standard techniques including culture colonies morphology, microscopy staining methods, and biochemical tests18.

**Biofilm production detection**

The biofilm was detected by the tissue culture method / microtiter plate method (TCA)19. *P. gingivalis* isolates were inoculated from fresh agar plates in 2 mL of Brain Heart Infusion (BHI) broth and incubated for 24 h at 37°C anaerobically. Then the cultures were diluted 1:40 with fresh medium (BHI broth with 1% glucose added); 200 μl of the sample was dispensed in the individual microtitration plate and incubated further 24 h at 37°C anaerobically. The content was removed again with subsequent washing with phosphate saline (pH 7.2) three times to remove free-floating sessile bacteria with gentle pecking - then the adherent bacteria, a biofilm product, was fixed with sodium acetate (2%) and stained with crystal violet (0.1% w/w). for 10-15 minutes. The liberated violet crystal solution was removed with triplicate wash with PBS, and then the plate was kept for drying. Finally, with 200 μl ethanol (95%) all wells were filled to release the dye from the well and the optical density (OD) was measured at the wavelength of 630 nm. The OD value was calculated for each negative test and control strain, and the OD cutoff values (ODc) were evaluated as previously described 19.

Antimicrobial susceptibility testing was performed using the disk diffusion methodaccording to CLSI[20]. Antimicrobial agents used in the study included amoxicillin(AM) 10μg, amoxicillin/clavulanic acid (2:1) (amoxy-clav) (AM-C) 10μg, tetracycline (TE 30μg), doxycycline (DO 30μg), clindamycin (DA 2 µg), azithromycin (AZM 15 µg), moxifloxacin (MFX 5µg), cefazolin (KZ 30µg), ceftriaxone (CRO 30µg), cefuroxime (CXM 30µg), cefotaxime (CTX 30µg) and metronidazole (MET 5µg) (Oxoid Ltd). Inocula of test strains were prepared in thioglycollate broth to a concentration of 0.5 MacFarland standard and inoculated onto brucella blood agar plates supplemented with hemin and menadione. The antibiotic discs were placed in the plate and the plates were then incubated anaerobically in a gas-pak jar at 37°C overnight. The inhibition zones were measuredand interpreted according to Clinical and Laboratory Standards Institute (CLSI) methodology [20]..

**DATA ANALYSIS**

The interpretative criteria for anaerobic sensitivity were applied to determine the breakpoints for amoxicillin, amoxicillin/clavulanic acid (2:1) (amoxy-clav), tetracycline, doxycycline, clindamycin, azithromycin, moxifloxacin, cefazolin, ceftriaxone, cefuroxime, cefotaxime and metronidazole 20.Since guidelines for the antibiotics used were not available for *P.gangivilis'* interpretive criteria for facultative anaerobic organisms, they were applied to these antibiotics. For the level of statistical significance of antibiotic resistance rate between *P.gingivalis* biofilm producers and non-producers, significance was assumed at *p*< 0.05.

**RESULTS**

When isolated *P.gangivilis*were exposed to biofilm detection by TCP method, 7 (23.3%) showed high biofilm formation capacity, 6 (20%) showed moderate biofilm formation capacity, while 17 (56.7%) showed non/weak formation capacity of biofilm. The overall rate biofilm formation was 43.3%(Table 1). *P.gingivalis*biofilms producing isolates showed a higher resistance rate than non/weak biofilms producingisolates, e.g amoxicillin (92.3% vs 64.7%, *p* = 0.08), azithromycin (58.8% vs 11.7, *p* =0.003), metronidazole (76.9% vs 29.4%, *p* = 0.08), 0.01) and clindamycin (84.6% vs 47.1, p = 0.03) (Table 2). Regarding all antibiotic sensitivity findings: cefotaxime, ceftriaxone and moxifloxacin showed excellent activity at 100% sensitivity, followed by amoxiclav (90%), tetracycline (83.3%), cefuroxime (80%), cefazolin (73.3%) and azithromycin (63.3%). In addition, Bacterial strains showed poor sensitivity to clindamycin, doxycycline, metronidazole and amoxicillin (Table 3).

**DISCUSSION**

Even though clinical isolates of *P. gingivalis*arelikely to be sensitive to the majority antimicrobial agents and usually do not generate *β-lactamase*, fairly little information is obtainable on in vitro antibiotic susceptibility. Moreover, antibiotic resistance among anaerobes is constantly rising which may be associated to the selective pressure applied by the use of antibiotics10,21.Determination of susceptibility to antimicrobials in vitro can be essential in certain conditions, for example, to screen patterns of sensitivity and resistance in a population and to assist in the choice of asuitable antibiotic when implied in endodontic therapy. The disc diffusion assay was evaluated for determination of the sensitivity of anaerobic bacteria against different antimicrobial agents and was found to be suitable 10,21.Recent indication shows that endodontic infection is straight related to bacterial invasion of dentine, the root canal system, and peri-root tissue. Treatment is mainly reliant on mechano-chemical remove infected pulp and dentine remnants to avoid re-infection. Failure rates due to contamination are alterable from 11-20% 22,23.The therapeutic method for endodontic infection is comparable to that of an anaerobic infection in general. Surgery acts a key role; debridement of necrotic tissue and drainage of pus collections is fundamental. On the other hand, in some cases such as puffiness, weakness, superficial erythema, lymphadenopathy, fever, or if surgical treatment cannot be executed due to the general condition of the patient, antimicrobial therapy must be determined with cautious choice of the antibiotic to be prescribed 21, 24.Establishing drug sensitivity patterns in pathogenic bacteria is avital step for risinga rational antimicrobial guide. In dentistry, once the use of antimicrobial drugs is required, the selection of antibiotic is established on sensitivity pattern research described from the international literature. It has been revealed that anaerobic bacteria can cause a number of critical human infections, and that they are becoming gradually more resistant to numerous of the conventional anti-anaerobic antibiotics currently in use. In reality, over latest years, resistance to various antimicrobial agents has been commonly described intercontinental and sensitivity patterns have become less predictable10,25.Therefore in patients with aggressive periodontitis, the majority clinicians commend matching antibiotic therapy10,26. Nevertheless, regrettably, neither adequate guidelines nor pattern of antimicrobial susceptibility to *P.gingivalis* are available from Yemen for appropriate antimicrobial therapy. The most common drugs used as part of periodontal therapy include amoxicillin, amoxicillin-clavulanic acid, tetracycline, azithromycin, clindamycin, moxifloxacin and metronidazole10,26,27. Conversely, taking into account the most common antibiotics prescribed for systemic diseases, there were additives to this panel that included cefazolin, cefuroxime, doxycycline, , cefotaxime and ceftriaxone. Even though *P. gingivilis* are facultative anaerobic organisms, antimicrobial susceptibility testing is performed for anaerobic bacteria. There are three different methods for this purpose including agar dilution, broth microdilution and MIC gradient method by E-test strips28, 29.In this study, a disc diffusion assay was used to test the antimicrobials for *P. gingivilis* as the results are similar to those of anaerobic bacteria disc diffusion methods with their standard scales for inhibition zone diameter being considered the “gold standard”. Several studies have examined the effect of different periodontal treatments on clinical and microbiological parameters in LAP10, 30, 31. To my knowledge, there are no publications on the pattern of antimicrobial susceptibility to *P. gingivilis* from Yemen.

In the present study, the studied isolates illustrated a high level of resistance to amoxicillin (76.7%) but excellent efficacy to amoxiclav (90% sensitive). In spite of this several researchers have revealed diverse results with moderate to high sensitivity to amoxicillin and usually excellent efficacy to amoxiclav10,31-34. The current study found a high level of resistance to metronidazole among the isolates (50%), and these results are higher than those reported by Kulik *et al.*26 where *P. gingivalis* was 9.5% resistant to metronidazole.Metronidazole resistance has not been reported much in the literature, while in the current study 15 strains of *P. gingivalis* were resistant to metronidazole. The sensitive finding of those studies showing 100% sensitivity to metronidazole may be that such data do not appear in the results because the experiment cannot be repeated. because these strains are no longer viable and false positives may have occurred. The discrepancy is usually caused by too much oxygen during incubation, which is the most common mechanism of false-resistance results with metronidazole because the occurrence of a growth inhibiting zone (death of anaerobic bacteria) is due to exposure to too much oxygen during administration of antibiotic discs 10.Azithromycin is a new generation semi-synthetic macrolide derivative of erythromycin that has been modified to create a broader spectrum of antibacterial activity and improve tissue penetration. However, in this study, 30% of the strains were resistant to azithromycin.Also in the current study, a high level of clindamycin resistance was found (63.3%) and this is different from the results of several other studies where clindamycin resistance was only 38% or less27,28.In the current study, doxycycline 46.7% had a sensitive and moderate inhibitory effect (53.3%) on *P. gingivalis*compared with tetracycline (83% sensitive) and 13.3% moderate. These results differ from those reported by Kulik *et al.* in Swaziland where they reported a sensitivity of 95.2% to doxycycline 26.

Fluoroquinolones are known to have a very good effect against oral bacteria including *P. gingivalis*. Among the various drugs in this group, moxifloxacin is used to treat a number of infections, including: respiratory infections, cellulitis, anthrax, intra-abdominal infections, endocarditis, meningitis, and tuberculosis. Moxifloxacin was patented in 1988 and approved for use in the United States in 1999 and is on the World Health Organization's List of Essential Medicines 35. Almost all researchers showed that moxifloxacin has excellent activity against oral microbes,32, 33-34, 36 a result similar to the results of the current study where the drug showed a high sensitivity of 100% (Table 2). Only a few studies discuss the activity of different cephalosporins on *P. gingivalis*strains 31, 32. The current study found the results to be highly variable. While cefotaxime and ceftriaxone showed very good efficacy (100%), the sensitivity rate for cefazolin was 73.3% and cefuroxime 80%. Although cefoxitin is the drug of choice from the LAB group for the treatment of anaerobic disease37,The selection of the current study includes the most common cephalosporins prescribed in Yemen for systemic/non-oral bacterial infections. The results clearly showed that cefotaxime and ceftriaxone, which belong to the third generation of cephalosporins and have a wider range of activity, have a better effect compared to cefazolin (1st generation) and cefuroxime (2nd generation) in inhibiting bacterial growth.

**CONCLUSION**

Even though the present results show a high sensitivity pattern for *P. gingivalis*strains, some resistance has been observed. Antibiotic resistance patterns can change over the years, making susceptibility testing essential and to promote careful selection of initial antibiotic therapy, as an adjuvant to endodontic therapy. Because resistance cannot be prevented, an attempt should be made to modify its progression by limiting the use of antibiotics and restricting prophylaxis to where it is of proven value.In single antibiotics, the development of resistance to azithromycin and cefazolin also appears to be important. The change of resistance between different members of the cephalosporin group is a factor that should be further investigated due to the lack of a sensitivity profile for these antibiotics and the interpretive criteria for oral bacteria. The disc diffusion methodis easy to implement, interpret and can be applied up to one isolation at a time. Similar studies with a large sample size and from other parts of the world should be conducted to obtain information on the effect of geographic distribution on the resistance pattern of *P. gingivalis*.

**ACKNOWLEDGMENTS**

The authors extend their thanks and appreciation to Genius University of Science and Technology, Dhamar City, Republic of Yemen, which supported this work, in particular Dr. Mohammed Mohammed Ali Al-Najhi, the generous scholar who usually supports medical education and research in Yemen. The authors also would like to acknowledge Faculty of Dentistry, Sana'a University and the Microbiology Department of the National Center of Public Health Laboratories (NCPHL) Sana'a, Yemen for support and provided working space and materials.

**CONFLICT OF INTEREST**

No conflict of interest associated with this work.

**Author’s Contribution**

**REFERENCES**

1-Hajishengallis G, Abe T., Maekawa T, Hajishengallis E, Lambris J D. Role of complement in host–microbe homeostasis of the periodontium. Seminars in immunology 2013: Elsevier, 65-72.

2- Zenobia C, Hajishengallis G. Porphyromonas gingivalis virulence factors involved in subversion of leukocytes and microbial dysbiosis. Virulence. 2015;6(3):236-243. doi:10.1080/21505594.2014.999567

3-Bostanci N, Belibasakis GN. *Porphyromonas gingivalis*: an invasive and evasive opportunistic oral pathogen. FEMS microbiology letters 2012: 333:1-9.

4- Jorth P, Turner KH, Gumus P, Nizam N, Buduneli N, Whiteley M. Metatranscriptomics of the human oral microbiome during health and disease. MBio 2014; 5:e01012-14; PMID:24692635; http://dx.doi.org/10.1128/mBio.01012-14 [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977359/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24692635)] [[CrossRef](https://dx.doi.org/10.1128/mBio.01012-14)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=MBio&title=Metatranscriptomics+of+the+human+oral+microbiome+during+health+and+disease&author=P+Jorth&author=KH+Turner&author=P+Gumus&author=N+Nizam&author=N+Buduneli&volume=5&publication_year=2014&pages=e01012-14&pmid=24692635&doi=10.1128/mBio.01012-14&)]

5- Alhasani AH, Ishag RA, Yahya Al-Akwa AAY, Al Shamahy HA, Al-labani MA. Association between the *Streptococcus mutans* biofilm formation and dental caries experience and antibiotics resistance in adult females. Universal Journal of Pharmaceutical Research 2020; 5(6):1-3. DOI: <https://doi.org/10.22270/ujpr.v5i5.478>

6-Al-Shamahy HA., *et al.* “Biofilm Formation and Antifungal Susceptibility of *Candida* Isolates from Oral Cavity of Denture Wearer and Free Denture Individuals”. EC Dental Science 19.10 (2020): 58-66.

7- Praveen NC, Rajesh A, Madan M, Chaurasia VR, Hiremath NV, Sharma AM. In vitro Evaluation of Antibacterial Efficacy of Pineapple Extract (Bromelain) on Periodontal Pathogens. J Int Oral Health 2014; 6(5): 96–98.

8-Ardila CM, Granada MI, Guzmán IC. Antibiotic resistance of subgingival species in chronic periodontitis patients. J Periodontal Res. 2010;45:557–63. [PubMed] [Google Scholar]

9-Abbas AM, Al-Kibsi TAM, Al-Akwa AAY, AL-Haddad KA, Al-Shamahy HA, Al-labani MA. Characterization and antibiotic sensitivity of bacteria in orofacial abscesses of odontogenic origin. Universal J Pharm Res 2020; 5(6):36-42. https://doi.org/10.22270/ujpr.v5i6.510

10-AL-Haddad KA, Ali Al-Najhi MM, Al-Akwa AAY, Al-Shamahy HA, Al-Sharani AA, Al-labani MA (2021) Antimicrobial Susceptibility of *Aggregatibacter Actinomycetemcomitans* Isolated from Localized Aggressive Periodontitis (Lap) Cases. J Dent Ora Heal Ad Re: JDOHAR:103. https://doi.org/10.1111/j.1600-0463.2007.apm\_630.x

11-Al-Haddad KA, Al-Najhi MMA, Abbas AKM, Al-Akwa AAY, Al-Shamahy HA, Al-labani MA. Clinical features, age and sex distributions, risk factors and the type of bacteria isolated in periodontitis patients in Sana'a, Yemen. Universal Journal of Pharmaceutical Research 2021; 6(1):1-8. DOI: <https://doi.org/10.22270/ujpr.v6i1.532>

12- Al-Kebsi A, Othman A, Abbas AK, Madar E, Al-Shamahy HA, Al-Gaffari K, Daname SM, Motareb F. “Oral *C. albicans* colonization and non-*Candida albicans Candida* colonization among university students, Yemen”. Universal Journal of Pharmaceutical Research 2017; 2(5):1-6. doi:https://doi.org/10.22270/ujpr.v2i5.R2.

13- Al-Sanabani, N., A. Al-Kebsi, H. Al-Shamahy, and A.-K. A Abbas. “Etiology and risk factors of stomatitis among Yemeni denture wearers”. Universal Journal of Pharmaceutical Research 2018; 3(1):1-6. doi:https://doi.org/10.22270/ujpr.v3i1.R9.

14- Al-Haddad KA, Al-dossary OE, Al-Shamahy HA. “Prevalence and associated factors of oral non-*candida albicans candida* carriage in denture wearers in Sana’a city- Yemen”. Universal Journal of Pharmaceutical Research 2018; 3(4):7-11. doi:https://doi.org/10.22270/ujpr.v3i4.176.

15-Al-Shami IZ, Al-Shamahy HA,Abdul Majeed ALA, Al- Ghaffari KM and Obeyah AA. Association between the salivary Streptococcus mutans levels and dental caries experience in adult females. On J Dent Oral Health 2018; 1(1):1-6. <https://doi.org/10.33552/OJDOH.2018.01.000505>

16-Mutaher NJA, AL-Haddad KA, Al-Akwa AAY, Al-labani MA, Al-Shamahy HA, Zabara AQMQ, Al- deen HMS. Prevalence and causes of traumatic dental injuries to anterior teeth among primary school children in Sana'a city, Yemen. Universal J Pharm Res 2020; 5(3):38-43. https://doi.org/10.22270/ujpr.v5i3.329

17- Al-Akwa AA, Zabara A, Al-Shamahy HA, Al-labani MA, Al-Ghaffari KM, Al-Mortada AM, Al-Haddad AM, and Al-Sharani AA. “Prevalence of *staphylococcus aureus* in dental infections and the occurrence of MRSA in isolates”. Universal Journal of Pharmaceutical Research 2020; 5( 2):1-6. doi:https://doi.org/10.22270/ujpr.v5i2.384.

18- Cheesbrough M. District laboratory practice in tropical countries. Cambridge: Cambridge University Press; 2010. <https://doi.org/10.1017/CBO9780511581304>

19- Stepanovic S, Vukovic D, Hola V, *et al.* Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by*Staphylococci*. Acta Patho Micro 2007; 115(8):891–899.

20- CLSI. Performance Standards for Antimicrobial Disc Susceptibility Tests. (11th edn.), Approved standard M02-A11– Publication of Clinical and Laboratory Standards Institute [CLSI), 2012, USA, 32.

21-Jacinto RC, Gomes BP, Shah HN, Ferraz CC, Zaia AA, Souza-Filho FJ. Incidence and antimicrobial susceptibility of *Porphyromonas gingivalis* isolated from mixed endodontic infections. Int Endod J. 2006 Jan;39(1):62-70. doi: 10.1111/j.1365-2591.2005.01053.x. PMID: 16409330

22-Meuric V, Martin B, Guyodo H, Rouillon A, Tamanai-Shacoori Z, Barloy-Hubler F, Bonnaure-Mallet M (February 2013). "*Treponema denticola* improves adhesive capacities of *Porphyromonas gingivalis*". Molecular Oral Microbiology 2013;  **28** (1):40-3.  [doi](https://en.wikipedia.org/wiki/Doi_%28identifier%29):[10.1111/omi.12004](https://doi.org/10.1111/omi.12004). [PMID](https://en.wikipedia.org/wiki/PMID_%28identifier%29) [23194417](https://pubmed.ncbi.nlm.nih.gov/23194417).

23- Baek KJ, Ji S, Kim YC, Choi Y. Association of the invasion ability of *Porphyromonas gingivalis* with the severity of periodontitis. *Virulence*. 2015;6(3):274-281. doi:10.1080/21505594.2014.1000764

24- Irshad M, van der Reijden WA, Crielaard W, Laine ML. "In vitro invasion and survival of Porphyromonas gingivalis in gingival fibroblasts; role of the capsule". Archivum Immunologiae et Therapiae Experimentalis 2012;  **60**(6): 469–76. [doi](https://en.wikipedia.org/wiki/Doi_%28identifier%29):[10.1007/s00005-012-0196-8](https://doi.org/10.1007/s00005-012-0196-8). [PMID](https://en.wikipedia.org/wiki/PMID_%28identifier%29) [22949096](https://pubmed.ncbi.nlm.nih.gov/22949096). [S2CID](https://en.wikipedia.org/wiki/S2CID_%28identifier%29) [14254746](https://api.semanticscholar.org/CorpusID%3A14254746).

25-Dominy SS, Lynch C, Ermini F, Benedyk M, et al. *Porphyromonas gingivalis* in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019 Jan 23;5(1):eaau3333. doi: 10.1126/sciadv.aau3333. PMID: 30746447; PMCID: PMC6357742.

26- Kulik EM, Thurnheer T, Karygianni L, Walter C, Sculean A, Eick S. Antibiotic Susceptibility Patterns of Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis Strains from Different Decades.  Antibiotics (Basel). 2019;8(4):253. Published 2019 Dec 6. doi:10.3390/antibiotics8040253

27- Xie Y., Chen J., He J., Miao X., Xu M., Wu X., Xu B., Yu L., Zhang W. Antimicrobial resistance and prevalence of resistance genes of obligate anaerobes isolated from periodontal abscesses. J. Periodontol. 2014;85:327–334. doi: 10.1902/jop.2013.130081. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23659425)] [[CrossRef](https://dx.doi.org/10.1902/jop.2013.130081)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J.+Periodontol.&title=Antimicrobial+resistance+and+prevalence+of+resistance+genes+of+obligate+anaerobes+isolated+from+periodontal+abscesses&author=Y.+Xie&author=J.+Chen&author=J.+He&author=X.+Miao&author=M.+Xu&volume=85&publication_year=2014&pages=327-334&pmid=23659425&doi=10.1902/jop.2013.130081&)]

28- Al-Ahmad A., Ameen H., Pelz K., Karygianni L., Wittmer A., Anderson A.C., Spitzmuller B., Hellwig E. Antibiotic resistance and capacity for biofilm formation of different bacteria isolated from endodontic infections associated with root-filled teeth. J. Endod. 2014;40:223–230. doi: 10.1016/j.joen.2013.07.023. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24461408)] [[CrossRef](https://dx.doi.org/10.1016/j.joen.2013.07.023)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J.+Endod.&title=Antibiotic+resistance+and+capacity+for+biofilm+formation+of+different+bacteria+isolated+from+endodontic+infections+associated+with+root-filled+teeth&author=A.+Al-Ahmad&author=H.+Ameen&author=K.+Pelz&author=L.+Karygianni&author=A.+Wittmer&volume=40&publication_year=2014&pages=223-230&pmid=24461408&doi=10.1016/j.joen.2013.07.023&)]

29-Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: Spectrum and susceptibility testing. Clin Microbiol Rev. 2013;26:526–46. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719496/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23824372)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin+Microbiol+Rev&title=Antianaerobic+antimicrobials:+Spectrum+and+susceptibility+testing&author=I+Brook&author=HM+Wexler&author=EJ+Goldstein&volume=26&publication_year=2013&pages=526-46&pmid=23824372&)]

30- Shaddox LM, Walker C. Microbial testing in periodontics: Value, limitations and future directions.  Periodontol 2000. 2009;50:25–38. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19388951)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Periodontol+2000&title=Microbial+testing+in+periodontics:+Value,+limitations+and+future+directions&author=LM+Shaddox&author=C+Walker&volume=50&publication_year=2009&pages=25-38&pmid=19388951&)]

31- Oettinger-Barak O, Dashper SG, Catmull DV, Adams GG, Sela MN, Machtei EE, et al. Antibiotic susceptibility of Aggregatibacter actinomycetemcomitans JP2 in a biofilm. J Oral Microbiol. 2013;5:1-8.  [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650220/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23671757)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Oral+Microbiol&title=Antibiotic+susceptibility+of+Aggregatibacter+actinomycetemcomitans+JP2+in+a+biofilm&author=O+Oettinger-Barak&author=SG+Dashper&author=DV+Catmull&author=GG+Adams&author=MN+Sela&volume=5&publication_year=2013&pages=1-8&)]

32- Bhat KG, Khot P, Patil S, Pattar G, Majukar S. Antimicrobial susceptibility pattern of oral isolates of *Aggregatibacter actinomycetemcomitans*. J Oral Maxillofac Pathol. 2019;23(2):231-235. doi:10.4103/jomfp.JOMFP\_123\_19.

33- Kulik EM, Lenkeit K, Chenaux S, Meyer J. Antimicrobial susceptibility of periodontopathogenic bacteria. J Antimicrob Chemother. 2008;61:1087–91. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18326855)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Antimicrob+Chemother&title=Antimicrobial+susceptibility+of+periodontopathogenic+bacteria&author=EM+Kulik&author=K+Lenkeit&author=S+Chenaux&author=J+Meyer&volume=61&publication_year=2008&pages=1087-91&pmid=18326855&)]

34- Müller HP, Holderrieth S, Burkhardt U, Höffler U. In vitro antimicrobial susceptibility of oral strains of Actinobacillus actinomycetemcomitans to seven antibiotics. J Clin Periodontol. 2002;29:736-42.  [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12390570)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Clin+Periodontol&title=In+vitro+antimicrobial+susceptibility+of+oral+strains+of+Actinobacillus+actinomycetemcomitans+to+seven+antibiotics&author=HP+M%C3%BCller&author=S+Holderrieth&author=U+Burkhardt&author=U+H%C3%B6ffler&volume=29&publication_year=2002&pages=736-42&pmid=12390570&)]

35-  [World Health Organization](https://en.wikipedia.org/wiki/World_Health_Organization). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. [hdl](https://en.wikipedia.org/wiki/Hdl_%28identifier%29):[10665/325771](https://hdl.handle.net/10665/325771). WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

36- van Winkelhoff AJ, Herrera D, Oteo A, Sanz M. Antimicrobial profiles of periodontal pathogens isolated from periodontitis patients in the Netherlands and Spain. J Clin Periodontol. 2005;32:893–8. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15998275)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Clin+Periodontol&title=Antimicrobial+profiles+of+periodontal+pathogens+isolated+from+periodontitis+patients+in+the+Netherlands+and+Spain&author=AJ+van+Winkelhoff&author=D+Herrera&author=A+Oteo&author=M+Sanz&volume=32&publication_year=2005&pages=893-8&pmid=15998275&)]

37- Lewis JS, Bush K. Antibacterial agents. In: Jorgensen JH, Pfaller MA, Carroll KC, Landry ML, Funke G, Richter SS, editors. Manual of Clinical Microbiology. 11th ed. Vol. 1. Washington, DC, USA: ASM Press; 2015. pp. 652–84. [Google ScholaTable 1: Biofilm detection by TCP method for *Porphyromonas gingivalis* isolatesfrom localized aggressive periodontitis (LAP) cases

|  |  |  |
| --- | --- | --- |
| **Biofilm formation** | **Number** | **Percentage** |
| High\* | 7 | 23.3 |
| Moderate \* | 6 | 20 |
| Total biofilm | 13 | 43.3 |
| Non/weak | 17 | 56.7 |
| Total *Porphyromonas gingivalis* isolates | 30 | 100 |

\*TCP-High OD ≥ 0.24; Moderate OD =0.127-0.24, Non/weak OD < 0.12

# Table 2: Antimicrobial susceptibility of *Porphyromonas gingivalis* isolates from localized aggressive periodontitis (LAP) cases

|  |  |  |  |
| --- | --- | --- | --- |
| **Tested Antibiotics (Disc concentration µg)****Inhibition Zone by mm (R IS)** | **Resistance** | intermediate | **Sensitive** |
| No  | % | No | % | No  | (%) |
|

|  |  |  |
| --- | --- | --- |
| Amoxicillin (AM 10µg)≤13 14-17≥18 |  |  |

 | 23 | 76.7 | 4  | 13.3 | 3 | 10 |
| Amoxicillin-clavulanic acid (10 µg)

|  |  |  |
| --- | --- | --- |
| ≤13  | 14-17  | ≥18  |

 | 2 | 6.7 | 1  | 3.3 | 27 | 90 |
| Azithromycin (AZM 15 µg)

|  |  |  |
| --- | --- | --- |
| ≤13  | 14-17  | ≥18  |

 | 9 | 30 | 2  | 6.7 | 19 | 63.3 |
| Clindamycin (DA 2 µg)

|  |  |  |
| --- | --- | --- |
| ≤14  | 15-16  | ≥17  |

 | 19 | 63.3 | 4  | 13.3 | 7 | 23.3 |
| Cefazolin (KZ 30 µg )

|  |  |  |
| --- | --- | --- |
| ≤14  | 15-17  | ≥18  |

 | 4 | 13.3 | 4  | 13.3 | 22  | 73.3 |
| Cefotaxime (CTX 30 µg )

|  |  |  |
| --- | --- | --- |
| ≤15  | 16-18  | ≥19  |

 | 00 | 00 | 00 | 00 | 30  | 100 |
| Ceftriaxone (CRO 30 µg )

|  |  |  |
| --- | --- | --- |
| ≤19  | 20-22  | ≥23  |

 | 00 | 00 | 00 | 00 | 30  | 100 |
| Cefuroxime (CXM 30 µg )

|  |  |  |
| --- | --- | --- |
| ≤14  | 15-22  | ≥23  |

 | 1 | 3.3 | 5  | 16.7 | 24 | 80 |
| Doxycycline (DO 30 µg )

|  |  |  |
| --- | --- | --- |
| ≤15  | 16-18  | ≥19  |

 | 00 | 00 | 16 | 53.3 | 14  | 46.7 |
| Metronidazole (MET 5 µg)

|  |  |  |
| --- | --- | --- |
| ≤20  | 20-25 | ≥26  |

 | 15 | 50 | 4  | 13.3 | 11 | 36.7 |
| Moxifloxacin (MFX 5 µg )

|  |  |  |
| --- | --- | --- |
| ≤15  | 16-18  | ≥19  |

 | 00 | 00 | 00  | 00 | 30 | 100 |
| Tetracycline (TE 30 µg )

|  |  |  |
| --- | --- | --- |
| ≤15  | 16-18 | ≥19  |

 | 1 | 3.3 | 4  | 13.3 | 25 | 83.3 |

R=Resistance, I= intermediate, S=Sensitive, mm=millimeter

# Table 3: Antibacterial resistance pattern of  *Porphyromonas gingivalis* associated with biofilm formation

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Antibiotics** | **Total** | **Biofilm producing** ***P.gingivalis*** | **Non-Biofilm** **producing *P.gingivalis***  | ***P*** |
| **No** | **%** | **NO** | **%** | **No** | **%** |
|

|  |  |  |
| --- | --- | --- |
| Amoxicillin  |  |  |

 | 23 | 76.7 | 12 | 92.3 | 11 | 64.7 | 0.08 |
| Amoxicillin-clavulanic acid  | 2 | 6.7 | 1 | 7.7 | 1 | 5.9 | 0.84 |
| Azithromycin  | 9 | 30 | 7 | 53.8 | 2 | 11.7 | 0.003\* |
| Clindamycin  | 19 | 63.3 | 11 | 84.6 | 8 | 47.1 | 0.03 |
| Cefazolin  | 4 | 13.3 | 3 | 23.1 | 1 | 5.9 | 0.17 |
| Cefotaxime  | 00 | 00 | 00 | 00 | 00 | 00 | 1.0 |
| Ceftriaxone  | 00 | 00 | 00 | 00 | 00 | 00 | 1.0 |
| Cefuroxime  | 1 | 3.3 | 1 | 7.7 | 00 | 00 | 0.25 |
| Doxycycline  | 00 | 00 | 00 | 00 | 00 | 00 | 1.0 |
| Metronidazole  | 15 | 50 | 10 | 76.9 | 5 | 29.4 | 0.01\* |
| Moxifloxacin  | 00 | 00 | 00 | 00 | 00 | 00 | 1.0 |
| Tetracycline  | 1 | 3.3 | 1 | 7.7 | 00 | 00 | 0.25 |
| **Total** | **30** | **100** | **13** | **43.3** | **17** | **56.7** | **-** |